MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Exelixis, Inc. (EXEL) Completes Filing Of Application For Thyroid Cancer Drug Cabozantinib 0 comments
    May 30, 2012 5:54 PM | about stocks: EXEL

    Exelixis is a biotechnology company committed to developing small molecule therapies for the treatment of cancers. The company's initial efforts are focused almost exclusively on cabozantinib, a proprietary drug it believes will be very effective in the treatment of patients suffering from thyroid cancer.

    The company announced today that it has completed the filing of its rolling New Drug Application (NDA) with the U.S. Food and Drug Administration for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer. The application was submitted under the FDA's 'fast track' designation, which has been set up to accelerate the review of an investigational therapy for an unmet medical need.

    As part of the regulatory filing, Exelixis requested a 'priority review' designation from the FDA. If the request is granted, the FDA should complete the review of the data pertaining to cabozantinib within six months of the date of receipt of the final submission.

    Exelixis filed for a priority review based on the results of a pivotal phase 3 trial in patients with advanced medullary thyroid cancer. In October 2011, the company reported top-line results from the trial, demonstrating that it had met its primary endpoint of improving progression-free survival (by 7.2 months) when compared to a placebo.

    For further information about Exelixis and its cabozantinib drug, please visit the company's website at www.exelixis.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: EXEL
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.